DK2861229T3 - Farmaceutisk sammensætning indeholdende nikotinsyre og/eller niko-tinamid og/eller tryptophan til positiv påvirkning af tarmmikrobiataen - Google Patents
Farmaceutisk sammensætning indeholdende nikotinsyre og/eller niko-tinamid og/eller tryptophan til positiv påvirkning af tarmmikrobiataen Download PDFInfo
- Publication number
- DK2861229T3 DK2861229T3 DK13728758.7T DK13728758T DK2861229T3 DK 2861229 T3 DK2861229 T3 DK 2861229T3 DK 13728758 T DK13728758 T DK 13728758T DK 2861229 T3 DK2861229 T3 DK 2861229T3
- Authority
- DK
- Denmark
- Prior art keywords
- nicotinamide
- tryptophan
- pharmaceutical composition
- composition containing
- nicotinic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102012011890 | 2012-06-15 | ||
| PCT/EP2013/062363 WO2013186355A1 (en) | 2012-06-15 | 2013-06-14 | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2861229T3 true DK2861229T3 (da) | 2021-01-18 |
Family
ID=47002494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13728758.7T DK2861229T3 (da) | 2012-06-15 | 2013-06-14 | Farmaceutisk sammensætning indeholdende nikotinsyre og/eller niko-tinamid og/eller tryptophan til positiv påvirkning af tarmmikrobiataen |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US10426765B2 (show.php) |
| EP (2) | EP3831379B1 (show.php) |
| JP (3) | JP6855165B2 (show.php) |
| KR (2) | KR20150021071A (show.php) |
| CN (2) | CN108273064A (show.php) |
| AR (1) | AR091465A1 (show.php) |
| AU (1) | AU2013276451B2 (show.php) |
| BR (1) | BR112014030835B1 (show.php) |
| CA (1) | CA2876540C (show.php) |
| CY (1) | CY1123999T1 (show.php) |
| DK (1) | DK2861229T3 (show.php) |
| ES (1) | ES2859758T3 (show.php) |
| HR (1) | HRP20210090T1 (show.php) |
| HU (1) | HUE053359T2 (show.php) |
| IL (1) | IL236205B (show.php) |
| IN (1) | IN2014DN10260A (show.php) |
| JO (1) | JO3578B1 (show.php) |
| LT (1) | LT2861229T (show.php) |
| MX (1) | MX370795B (show.php) |
| NZ (1) | NZ702297A (show.php) |
| PH (1) | PH12014502744A1 (show.php) |
| PL (1) | PL2861229T3 (show.php) |
| PT (1) | PT2861229T (show.php) |
| RS (1) | RS61288B1 (show.php) |
| RU (1) | RU2657797C2 (show.php) |
| SA (1) | SA113340643B1 (show.php) |
| SG (1) | SG11201408251SA (show.php) |
| SI (1) | SI2861229T1 (show.php) |
| SM (1) | SMT202100248T1 (show.php) |
| TW (1) | TWI624260B (show.php) |
| WO (1) | WO2013186355A1 (show.php) |
| ZA (1) | ZA201408922B (show.php) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014DN10260A (show.php) | 2012-06-15 | 2015-08-07 | Conaris Res Inst Ag | |
| ES2978920T3 (es) | 2013-06-05 | 2024-09-23 | Univ British Columbia | Compuestos antifibrogénicos, métodos y usos de los mismos |
| ES2785399T3 (es) * | 2013-06-14 | 2020-10-06 | Conaris Res Institute Ag | Formulación de nicotinamida de liberación prolongada |
| EP2884282A1 (en) | 2013-12-13 | 2015-06-17 | CONARIS research institute AG | Use of tryptophan as a biomarker for patient selection, dosing and therapy monitoring for pharmaceutical compositions targeting the intestinal microbiota in diseases featuring tryptophan deficiency |
| JP6895752B2 (ja) * | 2013-12-13 | 2021-06-30 | コナリス リサーチ インスティチュート アーゲー | ニコチン酸および／またはニコチンアミドを含む、腸内微生物叢を改変することにより血中脂質レベルに有益に影響を及ぼすための医薬組成物 |
| JP6554468B6 (ja) | 2013-12-13 | 2019-09-11 | コナリス リサーチ インスティチュート アーゲー | ニコチンアミドと５−アミノサリチル酸との組合せを含有する、腸内微生物叢に有益な影響を及ぼすため、かつ／または胃腸の炎症を処置するための医薬組成物 |
| EP3107553B1 (en) * | 2014-02-18 | 2021-12-01 | Universitätsklinikum Jena | Methods and compositions for intestinal microenvironment transfer |
| CN106413680A (zh) * | 2014-05-12 | 2017-02-15 | 荷兰联合利华有限公司 | 用于诱导抗微生物肽生成的烟酰胺 |
| CN105287561A (zh) * | 2015-11-25 | 2016-02-03 | 上海交通大学医学院附属瑞金医院 | 一种治疗溃疡性结肠炎的药物组合物 |
| BR112018071074B1 (pt) * | 2016-04-14 | 2023-10-03 | Chromadex Inc | Fórmula infantil |
| RU2738114C2 (ru) * | 2016-04-19 | 2020-12-08 | Конарис Рисёрч Инститьют Аг | Пероральные фармацевтические композиции никотинамида |
| KR102381586B1 (ko) | 2016-04-19 | 2022-04-04 | 훼링 비.브이. | 메살라진의 경구용 약제학적 조성물 |
| CN109718234A (zh) * | 2017-10-31 | 2019-05-07 | 中国农业大学 | L-色氨酸在缓解肠道炎症反应和屏障功能紊乱中的应用 |
| CN108935981A (zh) * | 2018-06-05 | 2018-12-07 | 西北农林科技大学 | 围产期奶山羊添加烟酰胺对羔羊糖脂代谢的影响及其机制 |
| WO2020166527A1 (ja) * | 2019-02-12 | 2020-08-20 | めぐみ 田中 | 乳幼児用飲食品、乳幼児の腸内環境の改善方法、及び乳幼児の免疫力の増強方法 |
| CN113573777A (zh) | 2019-03-28 | 2021-10-29 | 国立大学法人东北大学 | 癌的预防或治疗剂 |
| CN113398130A (zh) * | 2020-03-16 | 2021-09-17 | 广州市妇女儿童医疗中心（广州市妇幼保健院、广州市儿童医院、广州市妇婴医院、广州市妇幼保健计划生育服务中心） | 烟酰胺用于预防和治疗胃肠道功能紊乱的用途 |
| CN116635025A (zh) * | 2020-11-27 | 2023-08-22 | 康纳里斯研究院股份公司 | 用于缩短covid-19和其他病毒感染患者的症状消退时间的烟酰胺、烟酰胺前体和烟酰胺代谢物及其组合物 |
| WO2022112489A1 (en) * | 2020-11-27 | 2022-06-02 | Conaris Research Institute Ag | Nicotinamide, nicotinamide precursors and nicotinamide metabolites and compositions thereof for reducing the time to resolution of symptoms in patients with covid-19 and other viral infections |
| TW202308605A (zh) * | 2021-07-19 | 2023-03-01 | 日商明治控股股份有限公司 | 用於炎症性腸疾病之預防或改善之組合物、以及用於腸內細菌叢調節之組合物 |
| WO2023187003A1 (en) * | 2022-03-30 | 2023-10-05 | Conaris Research Institute Ag | Composition comprising nicotinamide, nicotinamide precursors, nicotinamide metabolites or combinations thereof for preventing or reducing one or more post-acute symptoms of infectious diseases |
| KR102789810B1 (ko) | 2023-02-06 | 2025-03-31 | 한림대학교 산학협력단 | 아토피 피부염 진단용 바이오마커 |
| CN117837697A (zh) * | 2023-12-22 | 2024-04-09 | 汕头大学 | 一种烟酰胺的应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6129930A (en) | 1993-09-20 | 2000-10-10 | Bova; David J. | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
| DE19524928A1 (de) * | 1995-07-08 | 1997-01-09 | Basf Ag | Verfahren zur Rektifikation von Gemischen hochsiedender luft- und/oder temperaturempfindlicher Substanzen, die eine hohe Trennleistung erfordern, im Feinvakuum, sowie für dieses Verfahren geeignete Kolonnen |
| US5846983A (en) * | 1996-02-09 | 1998-12-08 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
| US5736532A (en) * | 1996-02-14 | 1998-04-07 | Furda; Ivan | Multifunctional fat absorption and blood cholesterol reducing formulation comprising chitosan |
| GB9614902D0 (en) * | 1996-07-16 | 1996-09-04 | Rhodes John | Sustained release composition |
| JP2002533415A (ja) * | 1998-12-23 | 2002-10-08 | ジー．ディー．サール エルエルシー | 心臓血管に適用するための回腸胆汁酸輸送阻害剤およびニコチン酸誘導体の組み合わせ |
| US6713057B1 (en) | 1999-02-24 | 2004-03-30 | The Johns Hopkins University | Compositions and methods for modulating serum cholesterol |
| GB0015242D0 (en) | 2000-06-22 | 2000-08-16 | Nycomed Amersham Plc | Stabiliser for radiopharmaceuticals |
| WO2002011725A1 (en) | 2000-08-08 | 2002-02-14 | Shionogi & Co., Ltd. | Inflammatory cytokine production inhibitors |
| US20040185097A1 (en) | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
| WO2005072113A2 (en) | 2004-01-20 | 2005-08-11 | Harty Richard F | Compositions and methods of treatment for inflammatory diseases |
| US20060264409A1 (en) | 2004-01-20 | 2006-11-23 | Harty Richard F | Compositions and methods of treatment for inflammatory diseases |
| CA2565993C (en) | 2004-05-27 | 2011-08-16 | Antibe Therapeutics Inc. | Salt of 4-or 5- aminosalicylic acid |
| CA2581775A1 (en) * | 2004-09-27 | 2006-04-06 | Sigmoid Biotechnologies Limited | Dihydropyrimidine microcapsule - formulations |
| EP1920770A4 (en) * | 2005-07-01 | 2010-09-29 | Ajinomoto Kk | THERAPEUTIC AGENT AGAINST INFLAMMATORY DISEASE AND TNF ALPHA PRODUCTION DISEASE |
| EP2026651B1 (en) * | 2006-03-08 | 2013-04-17 | Cortria Corporation | Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries |
| ITMI20061932A1 (it) | 2006-10-09 | 2008-04-10 | Carlo Ghisalberti | Complessi a trasferimento di carica per uso medicale |
| EP1935422A1 (en) * | 2006-12-20 | 2008-06-25 | PEJO Iserlohn Heilmittel-und Diät-GmbH & Co.KG | Pharmaceutical composition comprising nicotinamide or nicotinic acid |
| US20090104171A1 (en) * | 2007-10-19 | 2009-04-23 | Pardee Joel D | Metabolic Enhancement Therapy |
| WO2009131537A1 (en) * | 2008-04-25 | 2009-10-29 | Karolinska Institutet Innovations Ab | New therapy of treatment of the irritable bowel syndrome. |
| JP2011521915A (ja) * | 2008-05-20 | 2011-07-28 | セレニス セラピューティクス エス．エー． | ナイアシン及びｎｓａｉｄ併用療法 |
| WO2009149058A2 (en) | 2008-06-02 | 2009-12-10 | Dr. Reddy's Laboratories Ltd. | Modified release niacin formulations |
| CA2739465C (en) | 2008-10-03 | 2017-01-31 | Dr. Falk Pharma Gmbh | Compositions and methods for the treatment of bowel diseases with granulated mesalamine |
| JP2011121889A (ja) | 2009-12-09 | 2011-06-23 | En Otsuka Pharmaceutical Co Ltd | 炎症性腸疾患用アミノ酸組成物 |
| JP2012102054A (ja) * | 2010-11-11 | 2012-05-31 | Kyodo Milk Industry Co Ltd | 腸内ポリアミン増強剤 |
| WO2012090224A1 (en) | 2010-12-29 | 2012-07-05 | Nutracryst Therapeutics Private Limited | Novel cocrystals / molecular salts of mesalamine to be used as improved anti-inflammatory drug |
| IN2014DN10260A (show.php) | 2012-06-15 | 2015-08-07 | Conaris Res Inst Ag | |
| ES2785399T3 (es) | 2013-06-14 | 2020-10-06 | Conaris Res Institute Ag | Formulación de nicotinamida de liberación prolongada |
| RU2738114C2 (ru) | 2016-04-19 | 2020-12-08 | Конарис Рисёрч Инститьют Аг | Пероральные фармацевтические композиции никотинамида |
| WO2022112489A1 (en) * | 2020-11-27 | 2022-06-02 | Conaris Research Institute Ag | Nicotinamide, nicotinamide precursors and nicotinamide metabolites and compositions thereof for reducing the time to resolution of symptoms in patients with covid-19 and other viral infections |
-
2013
- 2013-06-14 IN IN10260DEN2014 patent/IN2014DN10260A/en unknown
- 2013-06-14 KR KR20147036089A patent/KR20150021071A/ko not_active Ceased
- 2013-06-14 CN CN201810359182.XA patent/CN108273064A/zh active Pending
- 2013-06-14 MX MX2014015217A patent/MX370795B/es active IP Right Grant
- 2013-06-14 DK DK13728758.7T patent/DK2861229T3/da active
- 2013-06-14 AU AU2013276451A patent/AU2013276451B2/en active Active
- 2013-06-14 SM SM20210248T patent/SMT202100248T1/it unknown
- 2013-06-14 KR KR1020207002601A patent/KR102211832B1/ko active Active
- 2013-06-14 PL PL13728758T patent/PL2861229T3/pl unknown
- 2013-06-14 BR BR112014030835-7A patent/BR112014030835B1/pt active IP Right Grant
- 2013-06-14 LT LTEP13728758.7T patent/LT2861229T/lt unknown
- 2013-06-14 RS RS20201595A patent/RS61288B1/sr unknown
- 2013-06-14 HU HUE13728758A patent/HUE053359T2/hu unknown
- 2013-06-14 JP JP2015516627A patent/JP6855165B2/ja active Active
- 2013-06-14 ES ES13728758T patent/ES2859758T3/es active Active
- 2013-06-14 SG SG11201408251SA patent/SG11201408251SA/en unknown
- 2013-06-14 PT PT137287587T patent/PT2861229T/pt unknown
- 2013-06-14 WO PCT/EP2013/062363 patent/WO2013186355A1/en not_active Ceased
- 2013-06-14 RU RU2014148239A patent/RU2657797C2/ru active
- 2013-06-14 NZ NZ702297A patent/NZ702297A/en unknown
- 2013-06-14 EP EP20214819.3A patent/EP3831379B1/en active Active
- 2013-06-14 US US14/407,780 patent/US10426765B2/en active Active
- 2013-06-14 SI SI201331842T patent/SI2861229T1/sl unknown
- 2013-06-14 CA CA2876540A patent/CA2876540C/en active Active
- 2013-06-14 HR HRP20210090TT patent/HRP20210090T1/hr unknown
- 2013-06-14 EP EP13728758.7A patent/EP2861229B1/en active Active
- 2013-06-14 CN CN201380031622.4A patent/CN104363907A/zh active Pending
- 2013-06-15 SA SA113340643A patent/SA113340643B1/ar unknown
- 2013-06-16 JO JOP/2013/0182A patent/JO3578B1/ar active
- 2013-06-17 AR ARP130102127 patent/AR091465A1/es unknown
- 2013-06-17 TW TW102121395A patent/TWI624260B/zh active
-
2014
- 2014-12-04 ZA ZA2014/08922A patent/ZA201408922B/en unknown
- 2014-12-05 PH PH12014502744A patent/PH12014502744A1/en unknown
- 2014-12-11 IL IL236205A patent/IL236205B/en active IP Right Grant
-
2018
- 2018-12-13 JP JP2018233038A patent/JP2019069972A/ja active Pending
-
2019
- 2019-09-16 US US16/572,494 patent/US20200009124A1/en active Pending
-
2021
- 2021-03-02 CY CY20211100172T patent/CY1123999T1/el unknown
- 2021-10-15 JP JP2021169322A patent/JP2022017332A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2861229T3 (da) | Farmaceutisk sammensætning indeholdende nikotinsyre og/eller niko-tinamid og/eller tryptophan til positiv påvirkning af tarmmikrobiataen | |
| DK2804587T3 (da) | Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed | |
| DK2558133T3 (da) | Coatinger til fremstillingen og anvendelse af polyhydroxyalkanoat-lægemiddelindretninger | |
| DK2892912T3 (da) | C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf | |
| DK3238709T3 (da) | Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme | |
| DK3252160T3 (da) | Systemer, fremgangsmåder og sammensætninger med crispr-cas-bestanddele til sekvensmanipulation | |
| DK2970872T3 (da) | Mikroorganismer og fremgangsmåder til fremstilling af sialylerede og N-acetylglucosamin-holdige oligosaccharider | |
| HUE036797T2 (hu) | Oleanolsav C17-heteroaril-származékai és azok alkalmazási eljárásai | |
| DK2898061T3 (da) | Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande | |
| DK2818481T3 (da) | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer | |
| DK2917358T3 (da) | Sammensætninger og fremgangsmåder til biologisk fremstilling af fedtsyrederivater | |
| DK3079675T3 (da) | Farmaceutisk sammensætning indeholdende nikotinsyre og/eller nikotinamid til anvendelse til gavnlig påvirkning af blodlipidniveauer ved modificering af tarmmikrobiataen | |
| DK2729151T3 (da) | Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf | |
| DK3041489T3 (da) | Anvendelse af en sammensætning omfattende mikroorganismer til at øge tarmproduktionen af smørsyre, folsyre eller niacin og/eller at mindske tarmproduktionen af ravsyre | |
| DK2812046T3 (da) | Injektorapparat med fikseret stempel og fremgangsmåde til anvendelse deraf | |
| DK2632954T4 (da) | Midler og fremgangsmåder til behandling af dlbcl | |
| HUE039915T2 (hu) | Anthelmintikus vegyületek és készítmények és alkalmazásuk eljárása | |
| HUE042516T2 (hu) | Javított eljárás treprosztinilnek és származékainak elõállítására | |
| CO6970616A2 (es) | Composición herbicida que contiene ácido de 4-amino-3-cloro-6-(4-cloro-2-flúor -3-metoxifenil) piridina-2-carboxílico, o los derivados del mismo y fluroxipir, o los derivados del mismo | |
| DK2909334T3 (da) | Gensignaturer af inflammatoriske lidelser, som er relateret til leveren og Crohns sygdom | |
| ME02905B (me) | Heterociklična jedinjenja, medikamenti koji sadrže navedena jedinjenja, njihova primjena i postupak za njihovo dobijanje | |
| DK2985284T3 (da) | Dicarboxylsyre bisamid derivater, brug heraf, farmaceutiske sammensætninger baseret derpå og metoder til fremstilling af dicarboxylsyre bisamid derivater | |
| DK3098224T3 (da) | Pyranochromenyl-phenolderivat og farmaceutisk sammensætning til behandling af metabolisk syndrom eller inflammationssygdom | |
| DK2956165T3 (da) | Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner på Eimeria eller begrænsning af Eimeria-infektion | |
| DK2736888T3 (da) | 3-heteroaroylaminopropionsyrederivater og deres anvendelse som farmaceutika |